|Systematic (IUPAC) name|
|N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide|
|Pregnancy cat.||B2 (AU) B (US)|
|Legal status||POM (UK) ℞-only (US)|
|Excretion||Fecal (69%) and renal (24%)|
|Mol. mass||389.449 g/mol|
|(what is this?)|
Alfuzosin (INN, provided as the hydrochloride salt) is an α1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.
Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.
Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.
- Uroxatral (manufacturer's website)
- Alfuzosin (patient information)
- Sandoz Alfuzosin (Canadian product sheet)
- Alfuzosin (General information from the NIH)
|This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|